Drug Trial Radar · NCT06998407
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Aug 20, 2025
Primary completion
Aug 2028
Study completion Aug 2030
Sponsor
- Lead sponsor
- Avenzo Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).
Conditions
- HR+/HER2- Breast Cancer
- HR+, HER2-, Advanced Breast Cancer
Interventions
AVZO-021Drug
AVZO-021 is an oral selective CDK2 inhibitor
FulvestrantDrug
Antineoplastic agent, estrogen receptor antagonist
LetrozoleDrug
Antineoplastic agent, aromatase inhibitor
AVZO-023Drug
AVZO-023 is an oral selective CDK4 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)Time frame: Cycle 1 (28 Days)
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)Time frame: From baseline until end of study treatment or study completion (approximately 2 years)
- Determine the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Approximately 16 months
- Objective Response Rate (ORR) (Phase 2)Time frame: From baseline through disease progression or study completion (approximately 2 years)
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Avenzo Therapeutics Recruiting Site
Los Angeles, California · Recruiting
Avenzo Therapeutics Recruiting Site
Los Angeles, California · Recruiting
Avenzo Therapeutics Recruiting Site
New Haven, Connecticut · Recruiting
Avenzo Therapeutics Recruiting Site
Orlando, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Sarasota, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Tampa, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Boston, Massachusetts · Recruiting
Avenzo Therapeutics Recruiting Site
New York, New York · Recruiting
Avenzo Therapeutics Recruiting Site
Cleveland, Ohio · Recruiting
Avenzo Therapeutics Recruiting Site
Columbus, Ohio · Recruiting
Avenzo Therapeutics Recruiting Site
Nashville, Tennessee · Recruiting
Avenzo Therapeutics Recruiting Site
Fort Worth, Texas · Recruiting
Avenzo Therapeutics Recruiting Site
Houston, Texas · Recruiting
Avenzo Therapeutics Recruiting Site
San Antonio, Texas · Recruiting
Avenzo Therapeutics Recruiting Site
Fairfax, Virginia · Recruiting
Avenzo Therapeutics Recruiting Site
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.